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but a significant uptake of citrulline from the circulation 
(4.8 ± 1.6 µmol/L; P = 0.0138) next to many other amino 
acids. The kidneys showed a marked release of serine 
and alanine into the circulation (−58.0 ± 4.4 µmol/L and 
−61.8 ± 5.2 µmol/L, P < 0.0001), and a smaller, but statis-
tically significant release of tyrosine (−12.0 ± 1.3 µmol/L, 
P < 0.0001). The spleen only released taurine 
(−9.6 ± 3.3 µmol/L; P = 0.0078). Simultaneous blood 
sampling in different veins provides unique qualitative and 
quantitative information on integrative amino-acid physiol-
ogy, and reveals that the well-known intestinal glutamine–
citrulline pathway appears to be functional in the small 
intestine but not in the colon.
Keywords Amino acids · Interorgan metabolism · Gut 
microbiota · Obesity · Type 2 diabetes
Abbreviations
PPPD  Pylorus-preserving pancreatico-duodenectomy
BMI  Body mass index
5-SSA  5-Sulfosalicylic acid
HPLC  High-performance liquid chromatography
OPA  o-Phthalaldehyde
3-MPA  3-Mercaptopropionic acid
THF  Tetrahydrofuran
Introduction
Gut microbiota are increasingly implicated in the patho-
genesis of obesity and type 2 diabetes. The functional out-
put of the gut microbiota, in particular short-chain fatty 
acids and amino acids, seems to affect metabolic homeo-
stasis profoundly (Neis et al. 2015; Wang et al. 2011). Gut 
bacteria partly determine the bioavailability of amino acids 
Abstract Plasma levels of several amino acids are corre-
lated with metabolic dysregulation in obesity and type 2 
diabetes. To increase our understanding of human amino-
acid metabolism, we aimed to determine splanchnic inter-
organ amino-acid handling. Twenty patients planned to 
undergo a pylorus preserving pancreatico-duodenectomy 
were included in this study. Blood was sampled from the 
portal vein, hepatic vein, superior mesenteric vein, infe-
rior mesenteric vein, splenic vein, renal vein, and the 
radial artery during surgery. The difference between arte-
rial and venous concentrations of 21 amino acids was 
determined using liquid chromatography as a measure 
of amino-acid metabolism across a given organ. Whereas 
glutamine was significantly taken up by the small intestine 
(121.0 ± 23.8 µmol/L; P < 0.0001), citrulline was released 
(−36.1 ± 4.6 µmol/L; P < 0.0001). This, however, was not 
seen for the colon. Interestingly, the liver showed a small, 
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to the host by influencing dietary substrate metabolism and 
by directly providing amino acids to the host for uptake 
(Metges 2000). Indeed, the human distal gut microbiome 
contains a variety of gene clusters involved in amino-acid 
biosynthesis (Gill et al. 2006). Interestingly, several amino 
acids released by gut bacteria can serve as precursors for 
the synthesis of short-chain fatty acids (Barker 1981) 
which, in turn, appear to contribute to body weight gain 
(Schwiertz et al. 2010). In view of this, and considering the 
association between plasma levels of certain amino acids 
and metabolic dysregulation in obesity and type 2 diabe-
tes (McCormack et al. 2013; Newgard 2012; Newgard et al. 
2009), detailed knowledge on human splanchnic amino-
acid metabolism is critical to understanding overall meta-
bolic regulation.
Various body compartments have been demonstrated 
to play specialized roles in amino-acid homeostasis, tak-
ing up or releasing specific amino acids (Tizianello et al. 
1980). However, the separate roles of the splanchnic organs 
in amino-acid metabolism in humans remain unclear. This 
is largely attributable to the inaccessibility of these organs 
and their efferent vessels (van de Poll et al. 2007b). As a 
result, most available human data concern overall splanch-
nic balances, which include contributions from all organs 
in the splanchnic bed. Only few human studies have been 
able to differentiate between the different intestinal seg-
ments (Fujita and Yanaga 2007; Olde Damink et al. 2002).
In this study, we aimed to provide a comprehensive 
overview of human splanchnic amino-acid metabolism, 
studying not only the liver and the kidneys, but also the 
spleen as well as the small versus the large intestine. We 
hypothesized that amino-acid metabolism of the small vs. 
the large intestine differs given the impact of gut bacteria 
on amino-acid bioavailability and their uneven distribution 
over the intestine. We show that the well-known intestinal 
glutamine–citrulline pathway appears to be present in the 
small intestine but not in the colon in vivo. This knowledge 
may be applied to optimize dietary supplementation (Iwasa 
et al. 2010; Petzke et al. 2014; Zhang et al. 2007) of certain 
amino acids and can be used for theoretical modelling of 
amino-acid metabolism in humans.
Materials and methods
Patients
Patients planned to undergo a pylorus preserving pancre-
atico-duodenectomy (PPPD) as a treatment for benign or 
malignant tumors were invited to participate in this study 
at the surgical outpatient clinic of Maastricht University 
Medical Center (MUMC+). All patients were pre-enrolled 
before surgery after giving written informed consent. 
Patients with known parenchymal and/or inflammatory 
liver disease as well as inflammatory bowel disease, inborn 
errors of metabolism, and/or use of antibiotics prior to sur-
gery were excluded from the study. Moreover, excessive 
drinking (>20 alcoholic consumptions per week) and/or 
excessive smoking (>20 cigarettes per week) were exclu-
sion criteria. All patients were on a stable Western diet 
before surgery except for two patients who received nutri-
ent drinks to supplement their nutritional needs.
Permission for the study was granted by the local Medi-
cal Ethics Committee of Maastricht University Medi-
cal Center (MEC 11-3-084) and the study was conducted 
according to the ethical standards of the Helsinki Declara-
tion of 1975 and in accordance with the Medical Research 
Involving Human Subjects Act (WMO).
Study protocol
Anaesthesia was applied according to institutional routines 
as previously described (van de Poll et al. 2007b). Dur-
ing surgery, blood was sampled from the portal vein, one 
hepatic vein, the superior mesenteric vein, the inferior mes-
enteric vein, the splenic vein, and the right renal vein by 
direct puncture using 25G needles. Simultaneously, an arte-
rial blood sample was drawn from the radial artery catheter.
Amino‑acid analysis
Upon sampling, blood was transferred to pre-chilled hep-
arinized vacuum tubes (Becton-Dickinson Vacutainer, 
Franklin Lakes, NJ, USA) and centrifuged at 4 °C at 
3500 rpm (r/mm = 200) for 10 min (Centrifuge 5417C, 
Eppendorf, Hamburg, Germany) to fractionate whole 
blood. The resulting plasma was transferred into Eppen-
dorf cups, immediately frozen in liquid nitrogen, and 
stored at −80 °C. Before the amino-acid analysis, sam-
ples were thawed at 4 °C, whereupon the plasma samples 
were deproteinized with 5-sulfosalicylic acid (5-SSA) 
(4 mg/100 µL plasma), vortexed vigorously, and centri-
fuged at 4 °C at 23300 rpm in a Heraeus Biofuge Stratos 
centrifuge for 20 min. Ten microliters of the clear superna-
tant together with 10 µL of a 500-µM norvaline solution as 
internal standard were diluted with 980-µL ice-cold water 
in a 1.2-mL WISP vial and placed in the cooled sample-
storage compartment of the WISP 712B sample processor 
(van Eijk et al. 1993).
Equipment
The HPLC system consisted of two Jasco Model PU-980 
pumps, a Model 717 plus autosampler from Gilson, and a 
Spark column oven from Waters (Etten-Leur, The Neth-
erlands). The injection valve was equipped with a 20-µL 
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sample loading loop. Analyses were performed on a 3-µm 
Microsphere C18 Bisschoff Spherisorb ODS II column (Felig 
et al. 1970) set at 21 °C (Waters, Etten-Leur, The Nether-
lands). The 5-µm Microsphere C18 Allsphere ODS II pre-
column [7.5 mm × 4.6 mm (i.d.)] was filled with the same 
packing material. For the automated pre-column derivati-
zation, a WISP 712B sample processor was used, equipped 
with a cooled sample-storage compartment which can be 
loaded with up to 48 samples in capped vials. Peak moni-
toring was performed with a Model FP 1520 fluorescence 
detector equipped with a xenon lamp and a 12-µL flow-cell 
(Jasco Benelux, Utrecht, The Netherlands). Detection was 
performed using an excitation wavelength of 330 nm and an 
emission cut-off filter of 440 nm (van Eijk et al. 1993). The 
coefficient of variance for all analyses was less than 4 %.
Reagents and solvents
o-Phthalaldehyde (OPA) was obtained from Fisher Scien-
tific (Breda, The Netherlands) and 3-mercaptopropionic acid 
(3-MPA) from Sigma-Aldrich (Zwijndrecht, The Nether-
lands). The OPA-MPA derivatization reagent was prepared 
by dissolving 15 mg of OPA in 0.5 mL of methanol, followed 
by adding 3.5 mL of potassium borate buffer (1.0 M, pH 
10.08) and 15 µL of 3-MPA. ULC/MS grade methanol and 
acetonitrile were supplied by Biosolve (Valkenswaard, The 
Netherlands). An internal standard working solution was pre-
pared by diluting 10-mM norvaline in 50-mM hydrochloric 
acid. We used HPLC-grade water processed with a Milli-Q 
UF Plus water purification system (Millipore, Waters). Indi-
vidual amino acids were obtained from Sigma-Aldrich (Zwi-
jndrecht, The Netherlands) and Merck (Schiphol-Rijk, The 
Netherlands). Amino-acid standard solutions were prepared 
by dissolving pure amino acids in ULC/MS grade water to a 
final concentration of 250 µM for each amino acid. Solvents 
used were of chromatographic grade. Solvent A consisted of 
3.88-L 25-mM citric acid, adjusted to pH 6.8 with sodium 
hydroxide, containing 120 mL of tetrahydrofuran (THF) 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). Solvent B 
was prepared by mixing 550-mL 25-mM citric acid, 400-mL 
acetonitrile, and 60-mL THF.
Data processing
Amino-acid concentrations were calculated using the peak 
area relative to the area of the internal standard peak using 
the TotalChrom™ Chromatography Data System from Per-
kin Elmer instruments (Massachusetts, USA).
Arterial venous differences
To quantify the contribution of the small intestine, colon, 
portal drained viscera (PDV), splanchnic area, liver, spleen, 
and kidneys in producing or extracting amino acids, we cal-
culated arterial venous differences (ΔAV) as follows: ΔAV 
SMV = [A] − [SMV], ΔAV IMV = [A] − [IMV], ΔAV 
PDV = [A] − [PV], ΔAV splanchnic area = [A] − [HV], 
ΔAV liver = [A + 0.7 × PV] − 0.3 × [HV], ΔAV 
SV = [A] − [SV], and ΔAV RV = [A] − [RV] (Vrieze 
et al. 2012). In these equations, [SMV], [IMV], [PV], [HV], 
[SV], [RV], and [A] (Bouby et al. 1993) indicate supe-
rior mesenteric venous, inferior mesenteric venous, por-
tal venous, hepatic venous, splenic venous, renal venous, 
and arterial concentrations, respectively. Positive arterial 
venous differences indicate net amino-acid uptake, whilst 
negative arterial venous differences indicate net release.
Fractional extraction calculations
Fractional extraction of amino acids was calculated as 
[(A) − (V)]/A × 100, where A and V are the concentrations 
of amino acids in arterial and venous plasma, respectively. 
This calculation represents the percentage of amino-acid 
influx that is actually taken up from the bloodstream (Gari-
botto et al. 2003; van de Poll et al. 2007b).
Statistics
Results are presented as means (SEM). The non-paramet-
ric Friedman test with Dunn’s Multiple Comparison Tests 
matched per subject was used for assessing statistically sig-
nificant differences between arterial and venous concentra-
tions of each amino acid of interest using GraphPad Prism 
version 5.01 for Windows (GraphPad Prism Software, Inc., 
USA). The strength of the linear association between AV 
differences of different amino acids was determined using 
the Spearman correlation coefficient. P values below 0.05 
were considered statistically significant.
Results
Twenty patients were enrolled in this study. Patient charac-
teristics are shown in Table 1. Patients had a mean age of 
64 years and a mean body mass index (BMI) of 24.7 kg/m2; 
40 % was female.
Absolute amino‑acid concentrations in different 
abdominal veins
Table 2 shows the absolute arterial and venous plasma 
concentrations of 21 amino acids. The arterial concentra-
tions we measured in this study were comparable to those 
we previously published for a group of pre-operative elec-
tive surgical patients (Dejong et al. 1996). In each blood 
vessel, glutamine was the most concentrated amino acid, 
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with means ranging from 393.3 ± 5.3 µmol/L in the supe-
rior mesenteric vein to 518.1 ± 20.0 µmol/L in the radial 
artery. α-Aminobutyric acid, on the other hand, showed 
the lowest concentration, with the splenic vein display-
ing a lowest mean concentration of 18.1 ± 1.1 µmol/L. 
Table 3 shows the arterial venous differences of the 21 
amino acids measured for the small intestine, colon, por-
tal drained viscera (PDV), splanchnic area, liver, spleen, 
and kidneys.
Amino‑acid handling by the small intestine
Arterial venous differences of the different amino acids 
through the small intestine are displayed in Fig. 1a. As 
expected, glutamine was taken up in large amounts by 
the small intestine with a mean of 121.0 ± 23.8 µmol/L, 
while citrulline was released (−36.1 ± 4.6 µmol/L, both 
P < 0.0001). Glycine, asparagine, arginine, and alanine 
were significantly released by the small intestine as well, 
with a mean release of −57.9 ± 22.4 µmol/L (P = 0.0006), 
−4.0 ± 1.5 µmol/L (P < 0.0001), −17.7 ± 4.5 µmol/L 
(P < 0.0001), and −79.0 ± 10.1 µmol/L (P < 0.0001), 
respectively.
Amino‑acid handling by the colon
We next analyzed the arterial venous differences of the dif-
ferent amino acids through the colon (Fig. 1b). In contrast 
to the small intestine, both glutamine uptake and citrulline 
release by the colon were not significant. The only signifi-
cant difference that was found concerned alanine, which 
was released by the colon into the circulation with a mean 
of −36.7 ± 4.6 µmol/L (P < 0.0001). All other amino acids 
displayed only minor arterial venous differences.
Table 1  Baseline characteristics (n = 20)




Age (years) 64 (54–75)
BMI 24.7 (18.7–29.3)
Plasma flows (mL/min)
 Portal vein 320 (42)
 Hepatic artery 110 (23)
 Splanchnic 430 (47)
 Renal 606 (112)
Table 2  Absolute arterial and venous amino-acid concentrations (n = 20)








Splenic vein Renal vein
Glutamate 56.4 (6.5) 122.4 (15.8) 54.5 (6.8) 61.1 (10.0) 49.1 (13.9) 43.6 (5.6) 61.3 (7.6)
Asparagine 46.0 (3.0) 41.6 (3.1) 50.5 (3.8) 50.7 (6.7) 46.4 (6.7) 49.3 (3.7) 44.1 (2.1)
Serine 97.2 (4.7) 92.0 (5.3) 98.6 (3.6) 101.8 (6.0) 93.4 (5.1) 94.1 (4.6) 130.0 (8.4)
Glutamine 518.1 (20.0) 485.0 (20.3) 481.2 (18.7) 393.3 (5.3) 497.7 (4.2) 500.0 (18.8) 509.8 (21.3)
Histidine 68.8 (2.6) 65.0 (2.8) 73.1 (2.7) 72.7 (4.9) 71.3 (5.0) 72.3 (3.3) 71.9 (2.7)
Glycine 236.9 (20.3) 258.0 (33.3) 256.9 (27.9) 291.9 (12.2) 236.6 (12.3) 249.5 (32.0) 247.7 (35.2)
Threonine 112.6 (6.2) 107.2 (6.0) 118.4 (6.5) 114.7 (4.8) 110.8 (6.8) 109.0 (5.1) 119.9 (8.2)
Citrulline 28.8 (2.8) 34.6 (3.4) 44.2 (4.0) 65.2 (8.9) 30.4 (13.7) 30.0 (2.8) 22.3 (1.9)
Arginine 65.3 (5.1) 49.3 (5.8) 75.5 (4.7) 83.6 (5.9) 68.2 (4.9) 66.2 (4.6) 73.9 (27.3)
Alanine 254.7 (22.0) 189.9 (18.5) 307.1 (23.7) 323.2 (26) 284.0 (23.0) 265.0 (22.0) 294.8 (8.2)
Taurine 63.4 (5.3) 67.0 (3.8) 70.5 (6.4) 67.4 (6.4) 71.1 (9.0) 73.6 (8.0) 61.2 (5.2)
aaba 18.4 (1.1) 18.5 (1.1) 18.3 (1.1) 18.8 (6.1) 18.5 (5.8) 18.1 (1.1) 18.9 (1.3)
Tyrosine 52.1 (3.3) 44.4 (3.0) 50.6 (3.1) 54.9 (6.8) 52.5 (6.1) 51.7 (4.1) 58.0 (4.0)
Valine 188.8 (7.3) 190.0 (7.5) 194.7 (6.8) 201.0 (4.0) 187.4 (3.9) 193.2 (8.3) 185.2 (8.3)
Methionine 24.2 (1.6) 19.1 (1.6) 25.6 (1.1) 27.8 (8.4) 23.6 (6.4) 23.5 (1.5) 22.4 (1.9)
Isoleucine 63.9 (4.2) 63.6 (4.5) 66.7 (4.0) 68.8 (5.4) 65.2 (6.1) 61.5 (4.0) 62.3 (4.8)
Phenylalanine 52.4 (2.0) 49.7 (2.1) 56.1 (1.7) 56.4 (4.3) 55.0 (4.1) 54.9 (2.1) 53.2 (2.2)
Tryptophan 30.1 (1.8) 28.9 (1.7) 29.4 (1.6) 30.5 (5.1) 28.8 (5.5) 27.3 (1.3) 29.2 (1.6)
Leucine 114.3 (6.0) 115.0 (6.5) 124.3 (5.4) 124.4 (5.4) 116.6 (5.5) 122.8 (6.8) 118.4 (6.8)
Ornithine 63.1 (5.7) 76.3 (7.4) 61.5 (4.9) 58.3 (8.8) 61.4 (8.6) 67.3 (5.9) 73.1 (8.3)
Lysine 137.9 (7.8) 135.5 (6.4) 159.1 (6.8) 159.9 (4.7) 152.0 (5.0) 149.3 (5.5) 154.3 (6.9)
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Table 3  Amino-acid handling by abdominal organs (n = 20)
Results are presented as means (SEM)
Positive arterial venous differences indicate net amino-acid uptake, negative arterial venous differences indicate net release
* P values below 0.05 were considered statistically significant
Arterial venous differences 
(µmol/L)
Splanchnic area PDV Liver Small intestine Colon Spleen Kidneys
Glutamate −66.4 (13.1)* 2.4 (3.6) −74.0 (13.1)* −5.0 (4.2) 6.8 (2.8) 12.4 (3.2) −1.5 (3.2)
Asparagine 4.7 (1.3) −4.4 (1.3)* 8.4 (1.8)* −4.0 (1.5)* −0.2 (1.1) −3.0 (2.2) −5.5 (0.8)
Serine 4.6 (2.8) 0.6 (1.7) 4.6 (2.8) −5.0 (5.3) 4.3 (1.8) 2.6 (1.8) −58.0 (4.4)*
Glutamine 29.3 (7.3) 42.1 (8.7)* 1.3 (6.2) 121.0 (23.8)* 20.8 (13.3) 14.3 (10.5) 22.2 (17.5)
Histidine 3.1 (1.5) −3.2 (1.2) 6.0 (1.5)* −5.0 (2.2) −2.6 (2.6) −4.2 (2.4) −5.9 (1.8)
Glycine −24.0 (15.8) −14.8 (20.9)* −14.2 (13.4) −57.9 (22.4)* −10.8 (17.2) −15.5 (20.6) −0.8 (20.2)
Threonine 0.6 (3.0) −3.4 (1.8) 3.2 (3.2) −7.0 (3.3) 2.0 (2.7) −1.1 (3.1) −5.7 (3.2)
Citrulline −5.4 (1.1) −14.5 (2.1)* 4.8 (1.6)* −36.1 (4.6)* −2.4 (3.1) −0.8 (1.1) 17.3 (2.0)
Arginine 16.5 (3.9) −8.1 (2.1)* 21.8 (4.7)* −17.7 (4.5)* −0.8 (2.2) −0.3 (2.3) −14.6 (2.4)
Alanine 54.2 (11.9) −47.1 (5.3)* 86.3 (12.5)* −79.0 (10.1)* −36.7 (4.6)* −20.8 (6.1) −61.8 (5.2)*
Taurine −3.0 (3.5) −6.3 (2.5) 1.8 (3.7) −3.4 (2.7) −7.4 (2.7) −9.6 (3.3)* 8.3 (4.9)
aab 0.1 (0.6) 0.4 (0.5) −0.2 (0.6) −0.2 (0.4) 0.2 (0.5) 0.5 (0.6) −1.7 (0.4)
Tyrosine 7.8 (1.8)* 2.2 (2.2) 6.8 (1.7)* −2.7 (2.3) 0.0 (1.5) 0.5 (2.8) −12.0 (1.3)*
Valine 1.3 (3.8) −1.8 (2.9) 3.1 (3.3) −9.7 (4.5) 1.8 (3.1) −2.0 (5.1) 4.3 (5.2)
Methionine 4.9 (1.2)* −0.8 (1.0) 5.9 (1.1)* −3.7 (1.8) 0.9 (1.4) 0.5 (1.5) 5.4 (1.9)
Isoleucine 1.8 (1.5) −0.8 (1.5) 2.2 (1.5) −3.3 (1.8) −0.6 (1.7) 3.9 (2.2) 1.5 (3.2)
Phenylalanine 2.7 (1.0) −2.8 (1.1) 5.0 (1.0)* −4.0 (1.8) −2.2 (1.1) −2.5 (1.9) 0.5 (1.9)
Tryptophan 1.4 (0.7) 1.0 (0.8) 0.7 (0.5) −0.3 (0.9) 1.6 (1.5) 2.9 (1.2) 3.2 (1.6)
Leucine 1.2 (2.3) −6.6 (1.8)* 6.2 (2.4)* −8.2 (3.6) −2.1 (2.0) −6.7 (2.9) −13.1 (2.1)
Ornithine −12.4 (3.5) 3.0 (1.3) −14.9 (3.8)* 5.6 (3.4) 1.2 (2.6) −3.4 (3.5) −14.1 (5.7)
Lysine 3.5 (8.6) −20.1 (7.7)* 18.3 (5.1)* −20.9 (9.1) −14.1 (9.3) −10.3 (8.7) −30.3 (10.0)
Fig. 1a  Arterial venous amino-
acid concentration differences 
across the small intestine
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Amino‑acid handling by the spleen
Among the 21 amino acids analyzed, only taurine showed 
a significant arterial venous difference across the spleen 
(−9.6 ± 3.3 µmol/L; P < 0.0145, Fig. 1c). Compared with the 
other organs, amino-acid handling in the spleen appeared to be 
much more variable among the different subjects tested.
Amino‑acid handling by the liver
The liver showed a small but significant uptake of citrulline 
from the circulation: 4.8 ± 1.6 µmol/L; P < 0.0138 (Fig. 1d). 
The percentage of citrulline influx that was actually taken up 
from the bloodstream equaled 12.1 %. Conversely, ornith-
ine and especially glutamate were released by the liver into 
the circulation in larger quantities (−14.9 ± 3.8 µmol/L; 
P = 0.0011 and −74.0 ± 13.1 µmol/L; P = 0.0002, 
respectively). Many other amino acids were taken up by 
the liver to a small extent: asparagine (P = 0.0009), his-
tidine (P = 0.0041), tyrosine (P = 0.0033), methionine 
(P = 0.0005), phenylalanine (P = 0.0011), and leucine 
(P = 0.0161). In contrast, alanine uptake by the liver was 
much more prominent, with an arterial venous difference of 
86.3 ± 12.5 µmol/L, P = 0.0003.
Amino‑acid handling by the kidneys
The kidneys showed a marked release of serine and 
alanine into the circulation (−58.0 ± 4.4 µmol/L 
and −61.8 ± 5.2 µmol/L, P < 0.0001; Fig. 1e), and a 
smaller but statistically significant release of tyrosine 
(−12.0 ± 1.3 µmol/L, P < 0.0001). No amino acids were 
taken up by the kidneys to a significant extent.
Amino‑acid handling by the portal drained viscera
Whereas glutamine was significantly taken up by the por-
tal drained viscera with a mean of 42.1 ± 8.7 µmol/L 
(P < 0.0001), arginine, citrulline, asparagine, glycine, ala-
nine (all P < 0.0001), leucine (P = 0.0014), and lysine 
were all significantly released by the portal drained vis-
cera (Fig. 1f). The corresponding mean arterial venous 
differences were: −8.1 ± 2.1 µmol/L for arginine; 
−14.5 ± 2.1 µmol/L for citrulline; −4.4 ± 1.3 µmol/L 
for asparagine; −14.8 ± 20.9 µmol/L for glycine; 
−47.1 ± 5.3 µmol/L for alanine, −6.6 ± 1.8 µmol/L for 
leucine, and −20.1 ± 7.7 µmol/L for lysine.
Amino‑acid handling by the overall splanchnic area
The splanchnic area, including contributions from the liver 
as well as extrahepatic tissues (i.e., the gastrointestinal 
tract, spleen, and pancreas), released glutamate into the cir-
culation (−66.4 ± 13.1 µmol/L; P < 0.0001, Fig. 1g). Con-
versely, tyrosine and methionine were the only amino acids 
to be taken up by the splanchnic area, albeit to a much 
lower extent; 7.8 ± 1.8 µmol/L and 4.9 ± 1.2 µmol/L, 
respectively (both P < 0.0001).
Fig. 1b  Arterial venous amino-
acid concentration differences 
across the large intestine
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Fig. 1c  Arterial venous amino-
acid concentration differences 
across the spleen
Fig. 1d  Arterial venous amino-
acid concentration differences 
across the liver
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Discussion
In this study, we have explored amino-acid handling by 
separate splanchnic organs. In view of the increasingly 
acknowledged role of the gut microbiota in amino-acid 
metabolism and energy metabolism, we payed special atten-
tion to the differences in amino-acid handling between the 
large intestine, which is densely populated with bacteria, 
and the small intestine, which contains less bacteria. In line 
with pioneering observations in the isolated, vascularly per-
fused rat intestine (Windmueller et al. 1970) and from the 
intestine in vivo in a number of different animals (Wind-
mueller 1982), we found that glutamine was taken up in 
large amounts by the human small intestine. Interestingly, 
in these rat models, it seemed that the intestinal utiliza-
tion of glutamine was unrelated to the activities of the gut 
microbiota as glutamine extraction was quantitatively simi-
lar in germ-free rats compared with the conventional rats. 
However, the altered gut microbiota composition in obese 
animals (Backhed et al. 2004; Turnbaugh et al. 2006) may 
still influence intestinal glutamine metabolism, which has 
been shown to be altered in obesity (Osto et al. 2013; Wolff 
et al. 2009).
An important aspect of glutamine metabolism in the 
intestine is the resulting production of citrulline, which is 
the precursor of arginine synthesis in extrahepatic organs, 
including the kidneys (Wu et al. 1994). Consistent with 
observations in animal studies and in vivo studies in man 
(Fujita and Yanaga 2007; van de Poll et al. 2007a), we 
were able to find a positive association between glutamine 
extraction and citrulline release by the human small intes-
tine. The endogenous conversion of glutamine into citrul-
line by the small intestine seems to be of clinical impor-
tance (Garlick 2001) as decreased glutamine concentrations 
in the intestinal mucosa are associated with mucosal atro-
phy, as well as an impaired intestinal barrier function and 
bacterial translocation (Ding and Li 2003; Rao and Samak 
2012). All these features have been implicated in the patho-
genesis of obesity-related conditions, such as type 2 dia-
betes and non-alcoholic steatohepatitis (Shaw et al. 2012). 
Hence, glutamine supplementation may be effective in 
these metabolic disorders as it has been in other conditions 
(Nose et al. 2010; Zhang and Jiang 2013).
We found that glutamine extraction occurred in the small 
intestine as well as the colon. However, the mean frac-
tional extraction rate of glutamine was approximately six 
times higher in the small intestine (24.1 %) as compared 
with the colon (3.9 %). In accordance with earlier studies 
(Fujita and Yanaga 2007; Olde Damink et al. 2002), supe-
rior mesenteric venous citrulline levels were significantly 
higher than inferior mesenteric venous citrulline levels, 
implying that the small intestine is more important for the 
production of citrulline than the colon. Furthermore, the 
only amino acid to be released by the colon was alanine. 
Fig. 1e  Arterial venous amino-
acid concentration differences 
across the kidneys
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Whereas the quantitative main production site of alanine 
in the body is muscle, colonic alanine release may contrib-
ute to endogenous glucose production in the liver as well. 
The finding that the colon did not show any other arterial 
venous differences is interesting in view of the suggested 
role for colonic bacteria in amino-acid metabolism (Neis 
et al. 2015). It is thought that amino acids are not signifi-
cantly absorbed by the colonic mucosa, but rather inten-
sively metabolized by the colonic microbiota (Davila et al. 
2013). Partly, due to differences in microbiota abundance 
and composition along the gastrointestinal tract, bacterial 
amino-acid metabolism in the gut is likely to be compart-
ment specific. In addition, nutritional status appears to play 
a role as well. Bacterial amino-acid metabolism might still 
benefit the host when food resources are scarce to enhance 
ecosystem stability (Costello et al. 2010).
Regarding the proposed interorgan relation between cit-
rulline and arginine metabolism in the gut, the liver, and the 
kidneys (Houdijk et al. 1994), we were not able to dem-
onstrate significant renal citrulline uptake or renal argi-
nine release. Normally, arginine is released into the renal 
vein after being synthesized from citrulline taken up from 
the bloodstream (Chen and Baylis 2010; Dhanakoti et al. 
1990). The fact that we only observed a slight non-signif-
icant renal citrulline uptake could be related to our rela-
tively small data set. Interestingly, renal citrulline uptake 
was considerably higher than the rate at which citrulline 
was released from the splanchnic area, supporting that also 
other processes than glutamine metabolism provide citrul-
line for renal arginine synthesis (Castillo et al. 1996). In 
line with earlier findings in humans (Brosnan 1987; Tizi-
anello et al. 1980, 1985), our data show a net renal release 
of serine into the systemic circulation. In contrast to our 
data, those studies also showed a significant renal uptake of 
glycine, which was interpreted as evidence for conversion 
of glycine to serine in the kidneys. A possible explanation 
for this discrepancy is that glycine is probably also sup-
plied to the kidneys from sources other than direct uptake 
from the bloodstream (Brosnan 1987; Dejong et al. 1998; 
Pitts and MacLeod 1972) This, in turn, offers an additional 
explanation why glycine uptake accounts for only 30 % of 
the net renal release of serine (van de Poll et al. 2004). On 
average, 1.5 g glycine is taken up by the human kidneys 
per day (Tizianello et al. 1980), followed by a release of 
4 g serine per day (Tizianello et al. 1985). Next to serine, 
the kidneys also released significant amounts of alanine 
and tyrosine in our test subjects. Prior studies already eluci-
dated the conversion of phenylalanine to tyrosine and found 
that the kidney is the major source of circulating tyrosine 
as the kidneys alone would be capable of producing all the 
tyrosine needed by the body (van de Poll et al. 2004).
The general view of the liver being an organ which does 
not take up any citrulline was disproved by our data set. 
The fractional hepatic extraction of citrulline was 12.1 %. 
Fig. 1f  Arterial venous amino-
acid concentration differences 
across the portal drained viscera
170 E. P. J. G. Neis et al.
1 3
Although hepatic citrulline metabolism is still an unknown 
area, we can speculate that hepatic citrulline may serve for 
de novo arginine synthesis followed by nitric oxide synthe-
sis. Glutamate, on the other hand, was significantly released 
by the liver into the circulation together with ornithine. It 
is well known that the liver contains high levels of argin-
ase I, which converts approximately 15 % of plasma argi-
nine to ornithine and urea, and, finally, to glutamate (Silva 
et al. 2006; Wu and Morris 1998). Enteral supplementation 
of arginine to support gut function has, therefore, already 
proven to be ineffective (Cynober 1994). Besides, hepatic 
arginine uptake also serves other purposes in the liver, 
including protein synthesis. As a result, the liver releases 
significant amounts of ornithine and urea, as confirmed in 
this study, whereas it does not release significant amounts 
of arginine. Since our study showed hepatic uptake of argi-
nine accompanied by hepatic release of glutamate and to a 
smaller extent release of ornithine, we assume that arginine 
is partly degraded to glutamate in the liver, as supported by 
other studies (O’Sullivan et al. 1998; Wu and Morris 1998).
Finally, we found that the spleen released taurine into 
the circulation. Taurine, which is the most abundant amino 
acid in white blood cells, especially reaches high concen-
trations in tissues with a high oxidative activity and in 
tissues exposed to increased levels of oxidizing agents, 
including the spleen and kidneys (Marcinkiewicz and 
Kontny 2014). Since the spleen contains a high number 
of lymphocytes, the pronounced release of taurine by the 
spleen might reflect lymphocyte degradation, or taurine 
release by lymphocytes. 
Conclusion
In conclusion, we show that the well-known intestinal 
glutamine–citrulline pathway appears to be present in the 
human small intestine but not in the colon in vivo. Another 
interesting observation from this study is the significant 
release of taurine by the spleen. In relation to nutrition 
research, these additions to our knowledge on the physi-
ology of human amino-acid metabolism are important 
to develop (organ) specific nutritional support. Further-
more, in light of the health claims of pre- and probiotics, 
a detailed picture of the physiology of human amino-acid 
metabolism as provided in this study, its interaction with 
the microbiome, as well as the effects manipulation by 
altering the diet or the composition of the microbiota is of 
pivotal importance.
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